Next Article in Journal
Comparative Analysis of Serum (Anti)oxidative Status Parаmeters in Healthy Persons
Next Article in Special Issue
The Molecular Fingerprint of High Grade Serous Ovarian Cancer Reflects Its Fallopian Tube Origin
Previous Article in Journal
Early Exercise Protects against Cerebral Ischemic Injury through Inhibiting Neuron Apoptosis in Cortex in Rats
Previous Article in Special Issue
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(3), 6090-6105; doi:10.3390/ijms14036090

PAX2 Expression in Ovarian Cancer

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Biology Program, The University of Texas at Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Received: 25 January 2013 / Revised: 5 March 2013 / Accepted: 13 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
View Full-Text   |   Download PDF [1539 KB, 19 June 2014; original version 19 June 2014]   |  


PAX2 is one of nine PAX genes that regulate tissue development and cellular differentiation in embryos. However, the functional role of PAX2 in ovarian cancer is not known. Twenty-six ovarian cancer cell lines with different histology origins were screened for PAX2 expression. Two ovarian cancer cell lines: RMUGL (mucinous) and TOV21G (clear cell), with high PAX2 expression were chosen for further study. Knockdown PAX2 expression in these cell lines was achieved by lentiviral shRNAs targeting the PAX2 gene. PAX2 stable knockdown cells were characterized for cell proliferation, migration, apoptosis, protein profiles, and gene expression profiles. The result indicated that these stable PAX2 knockdown cells had reduced cell proliferation and migration. Microarray analysis indicated that several genes involved in growth inhibition and motility, such as G0S2, GREM1, and WFDC1, were up-regulated in PAX2 knockdown cells. On the other hand, over-expressing PAX2 in PAX2-negative ovarian cell lines suppressed their cell proliferation. In summary, PAX2 could have both oncogenic and tumor suppression functions, which might depend on the genetic content of the ovarian cancer cells. Further investigation of PAX2 in tumor suppression and mortality is warranty.
Keywords: PAX2; ovarian cancer; G0S2; WFDC1; GREM1; shRNA PAX2; ovarian cancer; G0S2; WFDC1; GREM1; shRNA
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary materials

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Song, H.; Kwan, S.-Y.; Izaguirre, D.I.; Zu, Z.; Tsang, Y.T.; Tung, C.S.; King, E.R.; Mok, S.C.; Gershenson, D.M.; Wong, K.-K. PAX2 Expression in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 6090-6105.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top